Pfizer (PFE) Begins Phase 2b/3 Clinical Trial for PF-06651600 for Treatment of Patients with Moderate to Severe Alopecia Areata

January 3, 2019 8:40 AM
Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles